Table 1 The characteristics and type of complications in complicated eyes treated for retinopathy of prematurity by intravitreal Bevacizumab
Eye number | GA (weeks) | BW (grams) | Gender | Time of first treatment (days after birth) | Zone of ROP | Stageof ROP | Presence of NVI | Complications |
|---|---|---|---|---|---|---|---|---|
1 | 27 | 850 | M | 73 | 1 | 3 | No | Visually lost eye |
2 | 27 | 850 | M | 73 | 1 | 3 | No | Visually lost eye |
3 | 26 | 800 | F | 95 | 2 | 3 | No | Visually lost eye |
4 | 26 | 800 | F | 95 | 2 | 3 | No | Visually lost eye |
5 | 29 | 1600 | M | 66 | 1 | 3 | Yes | Progression to stage 4A |
6 | 29 | 1600 | M | 66 | 1 | 3 | Yes | Progression to stage 4A |
7 | 28 | 1000 | F | 59 | 2 | 3 | No | Progression to stage 4A and 5 |
8 | 28 | 1360 | M | 38 | 2 | 3 | No | Cataract |
9 | 30 | 1550 | F | 77 | 2 | 3 | No | Progression to stage 4A |
10 | 30 | 1550 | F | 77 | 2 | 3 | No | Progression to stage 4A |
11 | 26 | 930 | F | 61 | 2 | 3 | No | Cataract |
12 | 29 | 1200 | F | 42 | 1 | 3 | No | Progression to stage 4A and 5 |
13 | 29 | 1200 | F | 42 | 1 | 3 | No | Progression to stage 4A and 5 |
14 | 27 | 1000 | F | 57 | 1 | 3 | No | Progression to stage 4A |
15 | 27 | 1000 | F | 57 | 1 | 3 | No | Progression to stage 4A |
16 | 28 | 1300 | F | 45 | 1 | 3 | Yes | Progression to stage 4A and 5 |
17 | 28 | 1300 | F | 45 | 1 | 3 | Yes | Progression to stage 4A |
18 | 25 | 895 | M | 70 | 1 | 3 | Yes | Vitreous hemorraghe |
19 | 28 | 1300 | F | 74 | 2 | 3 | No | Progression to stage 4A |
20 | 28 | 1300 | F | 74 | 2 | 3 | No | Progression to stage 4A |